Company intelligence / Profile preview

Seaport Therapeutics

Boston, Massachusetts, United States of Americaseaporttx.com ↗

Ownership: Public · SPTX
Employees: ~2
Development stage: Phase 2

Overview

Seaport's lead candidate SPT-300, an oral prodrug of allopregnanolone, has completed Phase 1 studies and is advancing into a Phase 2b study for major depressive disorder that has the potential to be registration-enabling. Additional data from the Phase 1 study was presented at ACNP Annual Meeting in December 2024.

Therapeutic areas: Psychiatry
Modalities: Small moleculesoral prodrugs
Industry: Biotech

Drug pipeline

7 assets

GlyphAllo

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.2B
Total revenue: $0
Enterprise value: $977.9M

Beyond the preview

Go deeper on Seaport Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seaport Therapeutics.

Explore the full profile